Recurrent Adult Immunoblastic Large Cell Lymphoma Recruiting Phase 2 Trials for DB08870 (Brentuximab vedotin)

IndicationStatusPhase
DBCOND0028500 (Recurrent Adult Immunoblastic Large Cell Lymphoma)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01703949Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ LymphomaTreatment